Add the ranked repurposing candidates, evidence views and graph exports
Browse filesSix derived tables from pd_kb.duckdb plus the top-10 shortlist and its mechanism/readout/pathway graphs (GraphML + Mermaid, all under 100 edges).
- graphs/pd_pathway_convergence.mmd +131 -0
- graphs/pd_ranking_top10.csv +11 -0
- graphs/pd_top10.graphml +472 -0
- graphs/pd_top10_mechanism.mmd +94 -0
- graphs/pd_top10_readouts.mmd +45 -0
- pd_drug_biomarker_readouts.parquet +3 -0
- pd_drug_candidates.parquet +3 -0
- pd_drug_target_evidence.parquet +3 -0
- pd_pathway_evidence.parquet +3 -0
- pd_ranking_top10.parquet +3 -0
- pd_undrugged_targets.parquet +3 -0
graphs/pd_pathway_convergence.mmd
ADDED
|
@@ -0,0 +1,131 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
%% Convergent PD pathways: toxin evidence + enrichment
|
| 2 |
+
flowchart LR
|
| 3 |
+
n0[["Parkinson disease"]]
|
| 4 |
+
n1["Detoxification of Reactive Oxygen Species"]
|
| 5 |
+
n2(["CAT"])
|
| 6 |
+
n3(["GPX1"])
|
| 7 |
+
n4(["GPX2"])
|
| 8 |
+
n5(["GPX3"])
|
| 9 |
+
n6(["SOD1"])
|
| 10 |
+
n7(["SOD2"])
|
| 11 |
+
n8(["SOD3"])
|
| 12 |
+
n9{{"chlorpyrifos"}}
|
| 13 |
+
n10{{"lead"}}
|
| 14 |
+
n11{{"manganese"}}
|
| 15 |
+
n12{{"mercury"}}
|
| 16 |
+
n13{{"paraquat"}}
|
| 17 |
+
n14{{"rotenone"}}
|
| 18 |
+
n15["Transcriptional activation of mitochondrial biogenesis"]
|
| 19 |
+
n16(["GABPA"])
|
| 20 |
+
n17(["PPARGC1B"])
|
| 21 |
+
n18{{"tetrachloroethylene"}}
|
| 22 |
+
n19["FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes"]
|
| 23 |
+
n20["Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation"]
|
| 24 |
+
n21["Interleukin-4 and Interleukin-13 signaling"]
|
| 25 |
+
n22(["AKT1"])
|
| 26 |
+
n23(["BCL2"])
|
| 27 |
+
n24(["IL6"])
|
| 28 |
+
n25(["MAOA"])
|
| 29 |
+
n26(["TNF"])
|
| 30 |
+
n27{{"mptp"}}
|
| 31 |
+
n28{{"trichloroethylene"}}
|
| 32 |
+
n29["Catecholamine biosynthesis"]
|
| 33 |
+
n30(["TH"])
|
| 34 |
+
n31["Biosynthesis of maresin-like SPMs"]
|
| 35 |
+
n32(["CYP2E1"])
|
| 36 |
+
n33["CYP2E1 reactions"]
|
| 37 |
+
n34["Synthesis of 5-eicosatetraenoic acids"]
|
| 38 |
+
n35(["GPX4"])
|
| 39 |
+
n36["Glutathione conjugation"]
|
| 40 |
+
n37(["HPGDS"])
|
| 41 |
+
n38{{"dieldrin"}}
|
| 42 |
+
n39["Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB"]
|
| 43 |
+
n40(["MAOB"])
|
| 44 |
+
n1 -->|q=0.015| n0
|
| 45 |
+
n2 -->|in pathway| n1
|
| 46 |
+
n3 -->|in pathway| n1
|
| 47 |
+
n4 -->|in pathway| n1
|
| 48 |
+
n5 -->|in pathway| n1
|
| 49 |
+
n6 -->|in pathway| n1
|
| 50 |
+
n7 -->|in pathway| n1
|
| 51 |
+
n8 -->|in pathway| n1
|
| 52 |
+
n9 -->|implicates| n1
|
| 53 |
+
n10 -->|implicates| n1
|
| 54 |
+
n11 -->|implicates| n1
|
| 55 |
+
n12 -->|implicates| n1
|
| 56 |
+
n13 -->|implicates| n1
|
| 57 |
+
n14 -->|implicates| n1
|
| 58 |
+
n15 -->|q=0.024| n0
|
| 59 |
+
n16 -->|in pathway| n15
|
| 60 |
+
n17 -->|in pathway| n15
|
| 61 |
+
n7 -->|in pathway| n15
|
| 62 |
+
n9 -->|implicates| n15
|
| 63 |
+
n10 -->|implicates| n15
|
| 64 |
+
n11 -->|implicates| n15
|
| 65 |
+
n12 -->|implicates| n15
|
| 66 |
+
n13 -->|implicates| n15
|
| 67 |
+
n14 -->|implicates| n15
|
| 68 |
+
n18 -->|implicates| n15
|
| 69 |
+
n19 -->|q=0.033| n0
|
| 70 |
+
n2 -->|in pathway| n19
|
| 71 |
+
n7 -->|in pathway| n19
|
| 72 |
+
n9 -->|implicates| n19
|
| 73 |
+
n10 -->|implicates| n19
|
| 74 |
+
n11 -->|implicates| n19
|
| 75 |
+
n12 -->|implicates| n19
|
| 76 |
+
n13 -->|implicates| n19
|
| 77 |
+
n14 -->|implicates| n19
|
| 78 |
+
n20 -->|q=0.015| n0
|
| 79 |
+
n6 -->|in pathway| n20
|
| 80 |
+
n7 -->|in pathway| n20
|
| 81 |
+
n9 -->|implicates| n20
|
| 82 |
+
n10 -->|implicates| n20
|
| 83 |
+
n11 -->|implicates| n20
|
| 84 |
+
n12 -->|implicates| n20
|
| 85 |
+
n13 -->|implicates| n20
|
| 86 |
+
n14 -->|implicates| n20
|
| 87 |
+
n21 -->|q=0.0064| n0
|
| 88 |
+
n22 -->|in pathway| n21
|
| 89 |
+
n23 -->|in pathway| n21
|
| 90 |
+
n24 -->|in pathway| n21
|
| 91 |
+
n25 -->|in pathway| n21
|
| 92 |
+
n26 -->|in pathway| n21
|
| 93 |
+
n27 -->|implicates| n21
|
| 94 |
+
n13 -->|implicates| n21
|
| 95 |
+
n14 -->|implicates| n21
|
| 96 |
+
n28 -->|implicates| n21
|
| 97 |
+
n29 -->|q=0.016| n0
|
| 98 |
+
n30 -->|in pathway| n29
|
| 99 |
+
n27 -->|implicates| n29
|
| 100 |
+
n14 -->|implicates| n29
|
| 101 |
+
n31 -->|q=0.022| n0
|
| 102 |
+
n32 -->|in pathway| n31
|
| 103 |
+
n28 -->|implicates| n31
|
| 104 |
+
n33 -->|q=0.048| n0
|
| 105 |
+
n32 -->|in pathway| n33
|
| 106 |
+
n28 -->|implicates| n33
|
| 107 |
+
n34 -->|q=0.035| n0
|
| 108 |
+
n3 -->|in pathway| n34
|
| 109 |
+
n4 -->|in pathway| n34
|
| 110 |
+
n35 -->|in pathway| n34
|
| 111 |
+
n12 -->|implicates| n34
|
| 112 |
+
n13 -->|implicates| n34
|
| 113 |
+
n36 -->|q=0.022| n0
|
| 114 |
+
n37 -->|in pathway| n36
|
| 115 |
+
n9 -->|implicates| n36
|
| 116 |
+
n38 -->|implicates| n36
|
| 117 |
+
n39 -->|q=0.0064| n0
|
| 118 |
+
n25 -->|in pathway| n39
|
| 119 |
+
n40 -->|in pathway| n39
|
| 120 |
+
n27 -->|implicates| n39
|
| 121 |
+
classDef drug fill:#ddf4ff,stroke:#0969da,color:#0a3069;
|
| 122 |
+
classDef anchor fill:#eeeeee,stroke:#6e7781,color:#24292f,stroke-dasharray:4 3;
|
| 123 |
+
classDef target fill:#fff8c5,stroke:#9a6700,color:#4d2d00;
|
| 124 |
+
classDef toxin fill:#ffebe9,stroke:#cf222e,color:#5a0f14;
|
| 125 |
+
classDef pathway fill:#dafbe1,stroke:#1a7f37,color:#0a3622;
|
| 126 |
+
classDef disease fill:#fbefff,stroke:#8250df,color:#3b1a5c;
|
| 127 |
+
classDef readout fill:#f6f8fa,stroke:#6e7781,color:#24292f;
|
| 128 |
+
class n2,n3,n4,n5,n6,n7,n8,n16,n17,n22,n23,n24,n25,n26,n30,n32,n35,n37,n40 target;
|
| 129 |
+
class n9,n10,n11,n12,n13,n14,n18,n27,n28,n38 toxin;
|
| 130 |
+
class n1,n15,n19,n20,n21,n29,n31,n33,n34,n36,n39 pathway;
|
| 131 |
+
class n0 disease;
|
graphs/pd_ranking_top10.csv
ADDED
|
@@ -0,0 +1,11 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
rank,drug,targets,toxins,modality,verdict,approval_year,priority_score,direction_component,pathway_component,toxin_component,cns_component,clinical_component,biomarker_component,n_protective,n_risk,n_ambiguous,best_pathway_qvalue,n_enriched_pathways,toxin_support,max_toxins_per_target,n_trials,n_late_phase_trials,n_pd_trials,n_neuro_trials,n_disease_readout_trials
|
| 2 |
+
1,Etanercept,TNF,trichloroethylene; mptp; paraquat; rotenone,biologic,candidate,1998,0.767,1.0,1.0,0.3504,0.7,0.8954,0.2203,1,0,0,0.006420344193912999,1,0.537422,4,354,181,0,5,78
|
| 3 |
+
2,Adalimumab,TNF,trichloroethylene; mptp; paraquat; rotenone,biologic,candidate,2002,0.6779,1.0,1.0,0.3504,0.15,0.9382,0.2217,1,0,0,0.006420344193912999,1,0.537422,4,469,272,0,0,104
|
| 4 |
+
3,Infliximab,TNF,trichloroethylene; mptp; paraquat; rotenone,biologic,candidate,1998,0.6698,1.0,1.0,0.3504,0.15,0.8975,0.1643,1,0,0,0.006420344193912999,1,0.537422,4,359,169,0,0,59
|
| 5 |
+
4,Tranylcypromine,MAOA; MAOB,mptp,small_molecule,candidate,1961,0.6622,1.0,1.0,0.1218,0.7,0.4129,0.0,2,0,0,0.006420344193912999,3,0.186904,1,14,6,0,1,0
|
| 6 |
+
5,Certolizumab,TNF,trichloroethylene; mptp; paraquat; rotenone,biologic,candidate,2008,0.6529,1.0,1.0,0.3504,0.15,0.7037,0.2,1,0,0,0.006420344193912999,1,0.537422,4,100,61,0,0,20
|
| 7 |
+
6,Golimumab,TNF,trichloroethylene; mptp; paraquat; rotenone,biologic,candidate,2009,0.6523,1.0,1.0,0.3504,0.15,0.7082,0.1845,1,0,0,0.006420344193912999,1,0.537422,4,103,53,0,0,19
|
| 8 |
+
7,Moclobemide,MAOA,mptp,small_molecule,candidate,1990,0.6345,1.0,1.0,0.0609,0.7,0.2454,0.0,1,0,0,0.006420344193912999,2,0.093452,1,4,2,0,1,0
|
| 9 |
+
8,Isocarboxazid,MAOA; MAOB,mptp,small_molecule,candidate,1959,0.6315,1.0,1.0,0.1218,0.7,0.1057,0.0,2,0,0,0.006420344193912999,3,0.186904,1,1,0,0,1,0
|
| 10 |
+
9,Phenelzine,MAOB; MAOA,mptp,small_molecule,candidate,1961,0.6292,1.0,1.0,0.1218,0.5,0.335,0.125,2,0,0,0.006420344193912999,3,0.186904,1,8,1,0,0,1
|
| 11 |
+
10,Bupropion,SLC6A3,mptp,small_molecule,candidate,1985,0.6254,1.0,0.5236,0.1168,0.7,0.8915,0.029,1,0,0,0.07114187315128005,0,0.179133,1,345,156,0,8,10
|
graphs/pd_top10.graphml
ADDED
|
@@ -0,0 +1,472 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
<?xml version="1.0" encoding="UTF-8"?>
|
| 2 |
+
<graphml xmlns="http://graphml.graphdrawing.org/xmlns">
|
| 3 |
+
<key id="n_best_pathway_qvalue" for="node" attr.name="best_pathway_qvalue" attr.type="double"/>
|
| 4 |
+
<key id="n_fold_enrichment" for="node" attr.name="fold_enrichment" attr.type="double"/>
|
| 5 |
+
<key id="n_kind" for="node" attr.name="kind" attr.type="string"/>
|
| 6 |
+
<key id="n_label" for="node" attr.name="label" attr.type="string"/>
|
| 7 |
+
<key id="n_modality" for="node" attr.name="modality" attr.type="string"/>
|
| 8 |
+
<key id="n_n_disease_readout_trials" for="node" attr.name="n_disease_readout_trials" attr.type="int"/>
|
| 9 |
+
<key id="n_n_toxins" for="node" attr.name="n_toxins" attr.type="int"/>
|
| 10 |
+
<key id="n_n_trials" for="node" attr.name="n_trials" attr.type="int"/>
|
| 11 |
+
<key id="n_pathway_size" for="node" attr.name="pathway_size" attr.type="int"/>
|
| 12 |
+
<key id="n_priority_score" for="node" attr.name="priority_score" attr.type="double"/>
|
| 13 |
+
<key id="n_qvalue" for="node" attr.name="qvalue" attr.type="double"/>
|
| 14 |
+
<key id="n_rank" for="node" attr.name="rank" attr.type="int"/>
|
| 15 |
+
<key id="n_toxin_support" for="node" attr.name="toxin_support" attr.type="double"/>
|
| 16 |
+
<key id="n_verdict" for="node" attr.name="verdict" attr.type="string"/>
|
| 17 |
+
<key id="e_direction" for="edge" attr.name="direction" attr.type="string"/>
|
| 18 |
+
<key id="e_direction_confidence" for="edge" attr.name="direction_confidence" attr.type="string"/>
|
| 19 |
+
<key id="e_kind" for="edge" attr.name="kind" attr.type="string"/>
|
| 20 |
+
<key id="e_label" for="edge" attr.name="label" attr.type="string"/>
|
| 21 |
+
<key id="e_qvalue" for="edge" attr.name="qvalue" attr.type="double"/>
|
| 22 |
+
<graph id="G" edgedefault="directed">
|
| 23 |
+
<node id="disease:Parkinson disease">
|
| 24 |
+
<data key="n_kind">disease</data>
|
| 25 |
+
<data key="n_label">Parkinson disease</data>
|
| 26 |
+
</node>
|
| 27 |
+
<node id="drug:Etanercept">
|
| 28 |
+
<data key="n_kind">drug</data>
|
| 29 |
+
<data key="n_label">Etanercept</data>
|
| 30 |
+
<data key="n_modality">biologic</data>
|
| 31 |
+
<data key="n_n_disease_readout_trials">78</data>
|
| 32 |
+
<data key="n_n_trials">354</data>
|
| 33 |
+
<data key="n_priority_score">0.767</data>
|
| 34 |
+
<data key="n_rank">1</data>
|
| 35 |
+
<data key="n_verdict">candidate</data>
|
| 36 |
+
</node>
|
| 37 |
+
<node id="target:TNF">
|
| 38 |
+
<data key="n_best_pathway_qvalue">0.006420344193912999</data>
|
| 39 |
+
<data key="n_kind">target</data>
|
| 40 |
+
<data key="n_label">TNF</data>
|
| 41 |
+
<data key="n_n_toxins">4</data>
|
| 42 |
+
<data key="n_toxin_support">0.5374</data>
|
| 43 |
+
</node>
|
| 44 |
+
<node id="toxin:rotenone">
|
| 45 |
+
<data key="n_kind">toxin</data>
|
| 46 |
+
<data key="n_label">rotenone</data>
|
| 47 |
+
</node>
|
| 48 |
+
<node id="toxin:trichloroethylene">
|
| 49 |
+
<data key="n_kind">toxin</data>
|
| 50 |
+
<data key="n_label">trichloroethylene</data>
|
| 51 |
+
</node>
|
| 52 |
+
<node id="toxin:paraquat">
|
| 53 |
+
<data key="n_kind">toxin</data>
|
| 54 |
+
<data key="n_label">paraquat</data>
|
| 55 |
+
</node>
|
| 56 |
+
<node id="toxin:mptp">
|
| 57 |
+
<data key="n_kind">toxin</data>
|
| 58 |
+
<data key="n_label">mptp</data>
|
| 59 |
+
</node>
|
| 60 |
+
<node id="drug:Rasagiline">
|
| 61 |
+
<data key="n_kind">anchor_drug</data>
|
| 62 |
+
<data key="n_label">Rasagiline</data>
|
| 63 |
+
<data key="n_modality">small_molecule</data>
|
| 64 |
+
<data key="n_n_disease_readout_trials">3</data>
|
| 65 |
+
<data key="n_n_trials">51</data>
|
| 66 |
+
<data key="n_priority_score">0.7253</data>
|
| 67 |
+
<data key="n_rank">0</data>
|
| 68 |
+
<data key="n_verdict">established_pd_therapy</data>
|
| 69 |
+
</node>
|
| 70 |
+
<node id="target:MAOB">
|
| 71 |
+
<data key="n_best_pathway_qvalue">0.006420344193912999</data>
|
| 72 |
+
<data key="n_kind">target</data>
|
| 73 |
+
<data key="n_label">MAOB</data>
|
| 74 |
+
<data key="n_n_toxins">1</data>
|
| 75 |
+
<data key="n_toxin_support">0.0935</data>
|
| 76 |
+
</node>
|
| 77 |
+
<node id="drug:Safinamide">
|
| 78 |
+
<data key="n_kind">anchor_drug</data>
|
| 79 |
+
<data key="n_label">Safinamide</data>
|
| 80 |
+
<data key="n_modality">small_molecule</data>
|
| 81 |
+
<data key="n_n_disease_readout_trials">0</data>
|
| 82 |
+
<data key="n_n_trials">25</data>
|
| 83 |
+
<data key="n_priority_score">0.7106</data>
|
| 84 |
+
<data key="n_rank">0</data>
|
| 85 |
+
<data key="n_verdict">established_pd_therapy</data>
|
| 86 |
+
</node>
|
| 87 |
+
<node id="drug:Adalimumab">
|
| 88 |
+
<data key="n_kind">drug</data>
|
| 89 |
+
<data key="n_label">Adalimumab</data>
|
| 90 |
+
<data key="n_modality">biologic</data>
|
| 91 |
+
<data key="n_n_disease_readout_trials">104</data>
|
| 92 |
+
<data key="n_n_trials">469</data>
|
| 93 |
+
<data key="n_priority_score">0.6779</data>
|
| 94 |
+
<data key="n_rank">2</data>
|
| 95 |
+
<data key="n_verdict">candidate</data>
|
| 96 |
+
</node>
|
| 97 |
+
<node id="drug:Methylphenidate">
|
| 98 |
+
<data key="n_kind">anchor_drug</data>
|
| 99 |
+
<data key="n_label">Methylphenidate</data>
|
| 100 |
+
<data key="n_modality">small_molecule</data>
|
| 101 |
+
<data key="n_n_disease_readout_trials">6</data>
|
| 102 |
+
<data key="n_n_trials">389</data>
|
| 103 |
+
<data key="n_priority_score">0.6773</data>
|
| 104 |
+
<data key="n_rank">0</data>
|
| 105 |
+
<data key="n_verdict">established_pd_therapy</data>
|
| 106 |
+
</node>
|
| 107 |
+
<node id="target:SLC6A3">
|
| 108 |
+
<data key="n_best_pathway_qvalue">0.07114187315128005</data>
|
| 109 |
+
<data key="n_kind">target</data>
|
| 110 |
+
<data key="n_label">SLC6A3</data>
|
| 111 |
+
<data key="n_n_toxins">1</data>
|
| 112 |
+
<data key="n_toxin_support">0.1791</data>
|
| 113 |
+
</node>
|
| 114 |
+
<node id="drug:Infliximab">
|
| 115 |
+
<data key="n_kind">drug</data>
|
| 116 |
+
<data key="n_label">Infliximab</data>
|
| 117 |
+
<data key="n_modality">biologic</data>
|
| 118 |
+
<data key="n_n_disease_readout_trials">59</data>
|
| 119 |
+
<data key="n_n_trials">359</data>
|
| 120 |
+
<data key="n_priority_score">0.6698</data>
|
| 121 |
+
<data key="n_rank">3</data>
|
| 122 |
+
<data key="n_verdict">candidate</data>
|
| 123 |
+
</node>
|
| 124 |
+
<node id="drug:Tranylcypromine">
|
| 125 |
+
<data key="n_kind">drug</data>
|
| 126 |
+
<data key="n_label">Tranylcypromine</data>
|
| 127 |
+
<data key="n_modality">small_molecule</data>
|
| 128 |
+
<data key="n_n_disease_readout_trials">0</data>
|
| 129 |
+
<data key="n_n_trials">14</data>
|
| 130 |
+
<data key="n_priority_score">0.6622</data>
|
| 131 |
+
<data key="n_rank">4</data>
|
| 132 |
+
<data key="n_verdict">candidate</data>
|
| 133 |
+
</node>
|
| 134 |
+
<node id="target:MAOA">
|
| 135 |
+
<data key="n_best_pathway_qvalue">0.006420344193912999</data>
|
| 136 |
+
<data key="n_kind">target</data>
|
| 137 |
+
<data key="n_label">MAOA</data>
|
| 138 |
+
<data key="n_n_toxins">1</data>
|
| 139 |
+
<data key="n_toxin_support">0.0935</data>
|
| 140 |
+
</node>
|
| 141 |
+
<node id="drug:Certolizumab">
|
| 142 |
+
<data key="n_kind">drug</data>
|
| 143 |
+
<data key="n_label">Certolizumab</data>
|
| 144 |
+
<data key="n_modality">biologic</data>
|
| 145 |
+
<data key="n_n_disease_readout_trials">20</data>
|
| 146 |
+
<data key="n_n_trials">100</data>
|
| 147 |
+
<data key="n_priority_score">0.6529</data>
|
| 148 |
+
<data key="n_rank">5</data>
|
| 149 |
+
<data key="n_verdict">candidate</data>
|
| 150 |
+
</node>
|
| 151 |
+
<node id="drug:Golimumab">
|
| 152 |
+
<data key="n_kind">drug</data>
|
| 153 |
+
<data key="n_label">Golimumab</data>
|
| 154 |
+
<data key="n_modality">biologic</data>
|
| 155 |
+
<data key="n_n_disease_readout_trials">19</data>
|
| 156 |
+
<data key="n_n_trials">103</data>
|
| 157 |
+
<data key="n_priority_score">0.6523</data>
|
| 158 |
+
<data key="n_rank">6</data>
|
| 159 |
+
<data key="n_verdict">candidate</data>
|
| 160 |
+
</node>
|
| 161 |
+
<node id="drug:Moclobemide">
|
| 162 |
+
<data key="n_kind">drug</data>
|
| 163 |
+
<data key="n_label">Moclobemide</data>
|
| 164 |
+
<data key="n_modality">small_molecule</data>
|
| 165 |
+
<data key="n_n_disease_readout_trials">0</data>
|
| 166 |
+
<data key="n_n_trials">4</data>
|
| 167 |
+
<data key="n_priority_score">0.6345</data>
|
| 168 |
+
<data key="n_rank">7</data>
|
| 169 |
+
<data key="n_verdict">candidate</data>
|
| 170 |
+
</node>
|
| 171 |
+
<node id="drug:Isocarboxazid">
|
| 172 |
+
<data key="n_kind">drug</data>
|
| 173 |
+
<data key="n_label">Isocarboxazid</data>
|
| 174 |
+
<data key="n_modality">small_molecule</data>
|
| 175 |
+
<data key="n_n_disease_readout_trials">0</data>
|
| 176 |
+
<data key="n_n_trials">1</data>
|
| 177 |
+
<data key="n_priority_score">0.6315</data>
|
| 178 |
+
<data key="n_rank">8</data>
|
| 179 |
+
<data key="n_verdict">candidate</data>
|
| 180 |
+
</node>
|
| 181 |
+
<node id="drug:Phenelzine">
|
| 182 |
+
<data key="n_kind">drug</data>
|
| 183 |
+
<data key="n_label">Phenelzine</data>
|
| 184 |
+
<data key="n_modality">small_molecule</data>
|
| 185 |
+
<data key="n_n_disease_readout_trials">1</data>
|
| 186 |
+
<data key="n_n_trials">8</data>
|
| 187 |
+
<data key="n_priority_score">0.6292</data>
|
| 188 |
+
<data key="n_rank">9</data>
|
| 189 |
+
<data key="n_verdict">candidate</data>
|
| 190 |
+
</node>
|
| 191 |
+
<node id="drug:Bupropion">
|
| 192 |
+
<data key="n_kind">drug</data>
|
| 193 |
+
<data key="n_label">Bupropion</data>
|
| 194 |
+
<data key="n_modality">small_molecule</data>
|
| 195 |
+
<data key="n_n_disease_readout_trials">10</data>
|
| 196 |
+
<data key="n_n_trials">345</data>
|
| 197 |
+
<data key="n_priority_score">0.6254</data>
|
| 198 |
+
<data key="n_rank">10</data>
|
| 199 |
+
<data key="n_verdict">candidate</data>
|
| 200 |
+
</node>
|
| 201 |
+
<node id="pathway:Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB">
|
| 202 |
+
<data key="n_fold_enrichment">120.5444</data>
|
| 203 |
+
<data key="n_kind">pathway</data>
|
| 204 |
+
<data key="n_label">Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB</data>
|
| 205 |
+
<data key="n_pathway_size">2</data>
|
| 206 |
+
<data key="n_qvalue">0.006420344193912999</data>
|
| 207 |
+
</node>
|
| 208 |
+
<node id="pathway:Interleukin-4 and Interleukin-13 signaling">
|
| 209 |
+
<data key="n_fold_enrichment">7.8131</data>
|
| 210 |
+
<data key="n_kind">pathway</data>
|
| 211 |
+
<data key="n_label">Interleukin-4 and Interleukin-13 signaling</data>
|
| 212 |
+
<data key="n_pathway_size">108</data>
|
| 213 |
+
<data key="n_qvalue">0.006420344193912999</data>
|
| 214 |
+
</node>
|
| 215 |
+
<edge id="e0" source="drug:Etanercept" target="target:TNF">
|
| 216 |
+
<data key="e_direction">protective</data>
|
| 217 |
+
<data key="e_direction_confidence">plausible</data>
|
| 218 |
+
<data key="e_kind">acts_on</data>
|
| 219 |
+
<data key="e_label">inhibitor</data>
|
| 220 |
+
</edge>
|
| 221 |
+
<edge id="e1" source="toxin:rotenone" target="target:TNF">
|
| 222 |
+
<data key="e_kind">implicates</data>
|
| 223 |
+
<data key="e_label">implicates</data>
|
| 224 |
+
</edge>
|
| 225 |
+
<edge id="e2" source="toxin:trichloroethylene" target="target:TNF">
|
| 226 |
+
<data key="e_kind">implicates</data>
|
| 227 |
+
<data key="e_label">implicates</data>
|
| 228 |
+
</edge>
|
| 229 |
+
<edge id="e3" source="toxin:paraquat" target="target:TNF">
|
| 230 |
+
<data key="e_kind">implicates</data>
|
| 231 |
+
<data key="e_label">implicates</data>
|
| 232 |
+
</edge>
|
| 233 |
+
<edge id="e4" source="toxin:mptp" target="target:TNF">
|
| 234 |
+
<data key="e_kind">implicates</data>
|
| 235 |
+
<data key="e_label">implicates</data>
|
| 236 |
+
</edge>
|
| 237 |
+
<edge id="e5" source="drug:Rasagiline" target="target:MAOB">
|
| 238 |
+
<data key="e_direction">protective</data>
|
| 239 |
+
<data key="e_direction_confidence">established</data>
|
| 240 |
+
<data key="e_kind">acts_on</data>
|
| 241 |
+
<data key="e_label">inhibitor</data>
|
| 242 |
+
</edge>
|
| 243 |
+
<edge id="e6" source="toxin:mptp" target="target:MAOB">
|
| 244 |
+
<data key="e_kind">implicates</data>
|
| 245 |
+
<data key="e_label">implicates</data>
|
| 246 |
+
</edge>
|
| 247 |
+
<edge id="e7" source="drug:Safinamide" target="target:MAOB">
|
| 248 |
+
<data key="e_direction">protective</data>
|
| 249 |
+
<data key="e_direction_confidence">established</data>
|
| 250 |
+
<data key="e_kind">acts_on</data>
|
| 251 |
+
<data key="e_label">inhibitor</data>
|
| 252 |
+
</edge>
|
| 253 |
+
<edge id="e8" source="toxin:mptp" target="target:MAOB">
|
| 254 |
+
<data key="e_kind">implicates</data>
|
| 255 |
+
<data key="e_label">implicates</data>
|
| 256 |
+
</edge>
|
| 257 |
+
<edge id="e9" source="drug:Adalimumab" target="target:TNF">
|
| 258 |
+
<data key="e_direction">protective</data>
|
| 259 |
+
<data key="e_direction_confidence">plausible</data>
|
| 260 |
+
<data key="e_kind">acts_on</data>
|
| 261 |
+
<data key="e_label">inhibitor</data>
|
| 262 |
+
</edge>
|
| 263 |
+
<edge id="e10" source="toxin:rotenone" target="target:TNF">
|
| 264 |
+
<data key="e_kind">implicates</data>
|
| 265 |
+
<data key="e_label">implicates</data>
|
| 266 |
+
</edge>
|
| 267 |
+
<edge id="e11" source="toxin:trichloroethylene" target="target:TNF">
|
| 268 |
+
<data key="e_kind">implicates</data>
|
| 269 |
+
<data key="e_label">implicates</data>
|
| 270 |
+
</edge>
|
| 271 |
+
<edge id="e12" source="toxin:paraquat" target="target:TNF">
|
| 272 |
+
<data key="e_kind">implicates</data>
|
| 273 |
+
<data key="e_label">implicates</data>
|
| 274 |
+
</edge>
|
| 275 |
+
<edge id="e13" source="toxin:mptp" target="target:TNF">
|
| 276 |
+
<data key="e_kind">implicates</data>
|
| 277 |
+
<data key="e_label">implicates</data>
|
| 278 |
+
</edge>
|
| 279 |
+
<edge id="e14" source="drug:Methylphenidate" target="target:SLC6A3">
|
| 280 |
+
<data key="e_direction">protective</data>
|
| 281 |
+
<data key="e_direction_confidence">plausible</data>
|
| 282 |
+
<data key="e_kind">acts_on</data>
|
| 283 |
+
<data key="e_label">inhibitor</data>
|
| 284 |
+
</edge>
|
| 285 |
+
<edge id="e15" source="toxin:mptp" target="target:SLC6A3">
|
| 286 |
+
<data key="e_kind">implicates</data>
|
| 287 |
+
<data key="e_label">implicates</data>
|
| 288 |
+
</edge>
|
| 289 |
+
<edge id="e16" source="drug:Infliximab" target="target:TNF">
|
| 290 |
+
<data key="e_direction">protective</data>
|
| 291 |
+
<data key="e_direction_confidence">plausible</data>
|
| 292 |
+
<data key="e_kind">acts_on</data>
|
| 293 |
+
<data key="e_label">inhibitor</data>
|
| 294 |
+
</edge>
|
| 295 |
+
<edge id="e17" source="toxin:rotenone" target="target:TNF">
|
| 296 |
+
<data key="e_kind">implicates</data>
|
| 297 |
+
<data key="e_label">implicates</data>
|
| 298 |
+
</edge>
|
| 299 |
+
<edge id="e18" source="toxin:trichloroethylene" target="target:TNF">
|
| 300 |
+
<data key="e_kind">implicates</data>
|
| 301 |
+
<data key="e_label">implicates</data>
|
| 302 |
+
</edge>
|
| 303 |
+
<edge id="e19" source="toxin:paraquat" target="target:TNF">
|
| 304 |
+
<data key="e_kind">implicates</data>
|
| 305 |
+
<data key="e_label">implicates</data>
|
| 306 |
+
</edge>
|
| 307 |
+
<edge id="e20" source="toxin:mptp" target="target:TNF">
|
| 308 |
+
<data key="e_kind">implicates</data>
|
| 309 |
+
<data key="e_label">implicates</data>
|
| 310 |
+
</edge>
|
| 311 |
+
<edge id="e21" source="drug:Tranylcypromine" target="target:MAOA">
|
| 312 |
+
<data key="e_direction">protective</data>
|
| 313 |
+
<data key="e_direction_confidence">plausible</data>
|
| 314 |
+
<data key="e_kind">acts_on</data>
|
| 315 |
+
<data key="e_label">inhibitor</data>
|
| 316 |
+
</edge>
|
| 317 |
+
<edge id="e22" source="toxin:mptp" target="target:MAOA">
|
| 318 |
+
<data key="e_kind">implicates</data>
|
| 319 |
+
<data key="e_label">implicates</data>
|
| 320 |
+
</edge>
|
| 321 |
+
<edge id="e23" source="drug:Tranylcypromine" target="target:MAOB">
|
| 322 |
+
<data key="e_direction">protective</data>
|
| 323 |
+
<data key="e_direction_confidence">established</data>
|
| 324 |
+
<data key="e_kind">acts_on</data>
|
| 325 |
+
<data key="e_label">inhibitor</data>
|
| 326 |
+
</edge>
|
| 327 |
+
<edge id="e24" source="toxin:mptp" target="target:MAOB">
|
| 328 |
+
<data key="e_kind">implicates</data>
|
| 329 |
+
<data key="e_label">implicates</data>
|
| 330 |
+
</edge>
|
| 331 |
+
<edge id="e25" source="drug:Certolizumab" target="target:TNF">
|
| 332 |
+
<data key="e_direction">protective</data>
|
| 333 |
+
<data key="e_direction_confidence">plausible</data>
|
| 334 |
+
<data key="e_kind">acts_on</data>
|
| 335 |
+
<data key="e_label">inhibitor</data>
|
| 336 |
+
</edge>
|
| 337 |
+
<edge id="e26" source="toxin:rotenone" target="target:TNF">
|
| 338 |
+
<data key="e_kind">implicates</data>
|
| 339 |
+
<data key="e_label">implicates</data>
|
| 340 |
+
</edge>
|
| 341 |
+
<edge id="e27" source="toxin:trichloroethylene" target="target:TNF">
|
| 342 |
+
<data key="e_kind">implicates</data>
|
| 343 |
+
<data key="e_label">implicates</data>
|
| 344 |
+
</edge>
|
| 345 |
+
<edge id="e28" source="toxin:paraquat" target="target:TNF">
|
| 346 |
+
<data key="e_kind">implicates</data>
|
| 347 |
+
<data key="e_label">implicates</data>
|
| 348 |
+
</edge>
|
| 349 |
+
<edge id="e29" source="toxin:mptp" target="target:TNF">
|
| 350 |
+
<data key="e_kind">implicates</data>
|
| 351 |
+
<data key="e_label">implicates</data>
|
| 352 |
+
</edge>
|
| 353 |
+
<edge id="e30" source="drug:Golimumab" target="target:TNF">
|
| 354 |
+
<data key="e_direction">protective</data>
|
| 355 |
+
<data key="e_direction_confidence">plausible</data>
|
| 356 |
+
<data key="e_kind">acts_on</data>
|
| 357 |
+
<data key="e_label">inhibitor</data>
|
| 358 |
+
</edge>
|
| 359 |
+
<edge id="e31" source="toxin:rotenone" target="target:TNF">
|
| 360 |
+
<data key="e_kind">implicates</data>
|
| 361 |
+
<data key="e_label">implicates</data>
|
| 362 |
+
</edge>
|
| 363 |
+
<edge id="e32" source="toxin:trichloroethylene" target="target:TNF">
|
| 364 |
+
<data key="e_kind">implicates</data>
|
| 365 |
+
<data key="e_label">implicates</data>
|
| 366 |
+
</edge>
|
| 367 |
+
<edge id="e33" source="toxin:paraquat" target="target:TNF">
|
| 368 |
+
<data key="e_kind">implicates</data>
|
| 369 |
+
<data key="e_label">implicates</data>
|
| 370 |
+
</edge>
|
| 371 |
+
<edge id="e34" source="toxin:mptp" target="target:TNF">
|
| 372 |
+
<data key="e_kind">implicates</data>
|
| 373 |
+
<data key="e_label">implicates</data>
|
| 374 |
+
</edge>
|
| 375 |
+
<edge id="e35" source="drug:Moclobemide" target="target:MAOA">
|
| 376 |
+
<data key="e_direction">protective</data>
|
| 377 |
+
<data key="e_direction_confidence">plausible</data>
|
| 378 |
+
<data key="e_kind">acts_on</data>
|
| 379 |
+
<data key="e_label">inhibitor</data>
|
| 380 |
+
</edge>
|
| 381 |
+
<edge id="e36" source="toxin:mptp" target="target:MAOA">
|
| 382 |
+
<data key="e_kind">implicates</data>
|
| 383 |
+
<data key="e_label">implicates</data>
|
| 384 |
+
</edge>
|
| 385 |
+
<edge id="e37" source="drug:Isocarboxazid" target="target:MAOA">
|
| 386 |
+
<data key="e_direction">protective</data>
|
| 387 |
+
<data key="e_direction_confidence">plausible</data>
|
| 388 |
+
<data key="e_kind">acts_on</data>
|
| 389 |
+
<data key="e_label">inhibitor</data>
|
| 390 |
+
</edge>
|
| 391 |
+
<edge id="e38" source="toxin:mptp" target="target:MAOA">
|
| 392 |
+
<data key="e_kind">implicates</data>
|
| 393 |
+
<data key="e_label">implicates</data>
|
| 394 |
+
</edge>
|
| 395 |
+
<edge id="e39" source="drug:Isocarboxazid" target="target:MAOB">
|
| 396 |
+
<data key="e_direction">protective</data>
|
| 397 |
+
<data key="e_direction_confidence">established</data>
|
| 398 |
+
<data key="e_kind">acts_on</data>
|
| 399 |
+
<data key="e_label">inhibitor</data>
|
| 400 |
+
</edge>
|
| 401 |
+
<edge id="e40" source="toxin:mptp" target="target:MAOB">
|
| 402 |
+
<data key="e_kind">implicates</data>
|
| 403 |
+
<data key="e_label">implicates</data>
|
| 404 |
+
</edge>
|
| 405 |
+
<edge id="e41" source="drug:Phenelzine" target="target:MAOA">
|
| 406 |
+
<data key="e_direction">protective</data>
|
| 407 |
+
<data key="e_direction_confidence">plausible</data>
|
| 408 |
+
<data key="e_kind">acts_on</data>
|
| 409 |
+
<data key="e_label">inhibitor</data>
|
| 410 |
+
</edge>
|
| 411 |
+
<edge id="e42" source="toxin:mptp" target="target:MAOA">
|
| 412 |
+
<data key="e_kind">implicates</data>
|
| 413 |
+
<data key="e_label">implicates</data>
|
| 414 |
+
</edge>
|
| 415 |
+
<edge id="e43" source="drug:Phenelzine" target="target:MAOB">
|
| 416 |
+
<data key="e_direction">protective</data>
|
| 417 |
+
<data key="e_direction_confidence">established</data>
|
| 418 |
+
<data key="e_kind">acts_on</data>
|
| 419 |
+
<data key="e_label">inhibitor</data>
|
| 420 |
+
</edge>
|
| 421 |
+
<edge id="e44" source="toxin:mptp" target="target:MAOB">
|
| 422 |
+
<data key="e_kind">implicates</data>
|
| 423 |
+
<data key="e_label">implicates</data>
|
| 424 |
+
</edge>
|
| 425 |
+
<edge id="e45" source="drug:Bupropion" target="target:SLC6A3">
|
| 426 |
+
<data key="e_direction">protective</data>
|
| 427 |
+
<data key="e_direction_confidence">plausible</data>
|
| 428 |
+
<data key="e_kind">acts_on</data>
|
| 429 |
+
<data key="e_label">inhibitor</data>
|
| 430 |
+
</edge>
|
| 431 |
+
<edge id="e46" source="toxin:mptp" target="target:SLC6A3">
|
| 432 |
+
<data key="e_kind">implicates</data>
|
| 433 |
+
<data key="e_label">implicates</data>
|
| 434 |
+
</edge>
|
| 435 |
+
<edge id="e47" source="target:MAOA" target="pathway:Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB">
|
| 436 |
+
<data key="e_kind">member_of</data>
|
| 437 |
+
<data key="e_label">in pathway</data>
|
| 438 |
+
</edge>
|
| 439 |
+
<edge id="e48" source="pathway:Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB" target="disease:Parkinson disease">
|
| 440 |
+
<data key="e_kind">enriched_in</data>
|
| 441 |
+
<data key="e_label">q=0.0064</data>
|
| 442 |
+
<data key="e_qvalue">0.006420344193912999</data>
|
| 443 |
+
</edge>
|
| 444 |
+
<edge id="e49" source="target:MAOA" target="pathway:Interleukin-4 and Interleukin-13 signaling">
|
| 445 |
+
<data key="e_kind">member_of</data>
|
| 446 |
+
<data key="e_label">in pathway</data>
|
| 447 |
+
</edge>
|
| 448 |
+
<edge id="e50" source="pathway:Interleukin-4 and Interleukin-13 signaling" target="disease:Parkinson disease">
|
| 449 |
+
<data key="e_kind">enriched_in</data>
|
| 450 |
+
<data key="e_label">q=0.0064</data>
|
| 451 |
+
<data key="e_qvalue">0.006420344193912999</data>
|
| 452 |
+
</edge>
|
| 453 |
+
<edge id="e51" source="target:MAOB" target="pathway:Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB">
|
| 454 |
+
<data key="e_kind">member_of</data>
|
| 455 |
+
<data key="e_label">in pathway</data>
|
| 456 |
+
</edge>
|
| 457 |
+
<edge id="e52" source="pathway:Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB" target="disease:Parkinson disease">
|
| 458 |
+
<data key="e_kind">enriched_in</data>
|
| 459 |
+
<data key="e_label">q=0.0064</data>
|
| 460 |
+
<data key="e_qvalue">0.006420344193912999</data>
|
| 461 |
+
</edge>
|
| 462 |
+
<edge id="e53" source="target:TNF" target="pathway:Interleukin-4 and Interleukin-13 signaling">
|
| 463 |
+
<data key="e_kind">member_of</data>
|
| 464 |
+
<data key="e_label">in pathway</data>
|
| 465 |
+
</edge>
|
| 466 |
+
<edge id="e54" source="pathway:Interleukin-4 and Interleukin-13 signaling" target="disease:Parkinson disease">
|
| 467 |
+
<data key="e_kind">enriched_in</data>
|
| 468 |
+
<data key="e_label">q=0.0064</data>
|
| 469 |
+
<data key="e_qvalue">0.006420344193912999</data>
|
| 470 |
+
</edge>
|
| 471 |
+
</graph>
|
| 472 |
+
</graphml>
|
graphs/pd_top10_mechanism.mmd
ADDED
|
@@ -0,0 +1,94 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
%% Top PD repurposing candidates: toxin, target and pathway evidence
|
| 2 |
+
flowchart LR
|
| 3 |
+
n0[["Parkinson disease"]]
|
| 4 |
+
n1["1. Etanercept"]
|
| 5 |
+
n2(["TNF"])
|
| 6 |
+
n3{{"rotenone"}}
|
| 7 |
+
n4{{"trichloroethylene"}}
|
| 8 |
+
n5{{"paraquat"}}
|
| 9 |
+
n6{{"mptp"}}
|
| 10 |
+
n7["Rasagiline (approved for PD)"]
|
| 11 |
+
n8(["MAOB"])
|
| 12 |
+
n9["Safinamide (approved for PD)"]
|
| 13 |
+
n10["2. Adalimumab"]
|
| 14 |
+
n11["Methylphenidate (approved for PD)"]
|
| 15 |
+
n12(["SLC6A3"])
|
| 16 |
+
n13["3. Infliximab"]
|
| 17 |
+
n14["4. Tranylcypromine"]
|
| 18 |
+
n15(["MAOA"])
|
| 19 |
+
n16["5. Certolizumab"]
|
| 20 |
+
n17["6. Golimumab"]
|
| 21 |
+
n18["7. Moclobemide"]
|
| 22 |
+
n19["8. Isocarboxazid"]
|
| 23 |
+
n20["9. Phenelzine"]
|
| 24 |
+
n21["10. Bupropion"]
|
| 25 |
+
n22["Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB"]
|
| 26 |
+
n23["Interleukin-4 and Interleukin-13 signaling"]
|
| 27 |
+
n1 -->|inhibitor| n2
|
| 28 |
+
n3 -->|implicates| n2
|
| 29 |
+
n4 -->|implicates| n2
|
| 30 |
+
n5 -->|implicates| n2
|
| 31 |
+
n6 -->|implicates| n2
|
| 32 |
+
n7 -->|inhibitor| n8
|
| 33 |
+
n6 -->|implicates| n8
|
| 34 |
+
n9 -->|inhibitor| n8
|
| 35 |
+
n6 -->|implicates| n8
|
| 36 |
+
n10 -->|inhibitor| n2
|
| 37 |
+
n3 -->|implicates| n2
|
| 38 |
+
n4 -->|implicates| n2
|
| 39 |
+
n5 -->|implicates| n2
|
| 40 |
+
n6 -->|implicates| n2
|
| 41 |
+
n11 -->|inhibitor| n12
|
| 42 |
+
n6 -->|implicates| n12
|
| 43 |
+
n13 -->|inhibitor| n2
|
| 44 |
+
n3 -->|implicates| n2
|
| 45 |
+
n4 -->|implicates| n2
|
| 46 |
+
n5 -->|implicates| n2
|
| 47 |
+
n6 -->|implicates| n2
|
| 48 |
+
n14 -->|inhibitor| n15
|
| 49 |
+
n6 -->|implicates| n15
|
| 50 |
+
n14 -->|inhibitor| n8
|
| 51 |
+
n6 -->|implicates| n8
|
| 52 |
+
n16 -->|inhibitor| n2
|
| 53 |
+
n3 -->|implicates| n2
|
| 54 |
+
n4 -->|implicates| n2
|
| 55 |
+
n5 -->|implicates| n2
|
| 56 |
+
n6 -->|implicates| n2
|
| 57 |
+
n17 -->|inhibitor| n2
|
| 58 |
+
n3 -->|implicates| n2
|
| 59 |
+
n4 -->|implicates| n2
|
| 60 |
+
n5 -->|implicates| n2
|
| 61 |
+
n6 -->|implicates| n2
|
| 62 |
+
n18 -->|inhibitor| n15
|
| 63 |
+
n6 -->|implicates| n15
|
| 64 |
+
n19 -->|inhibitor| n15
|
| 65 |
+
n6 -->|implicates| n15
|
| 66 |
+
n19 -->|inhibitor| n8
|
| 67 |
+
n6 -->|implicates| n8
|
| 68 |
+
n20 -->|inhibitor| n15
|
| 69 |
+
n6 -->|implicates| n15
|
| 70 |
+
n20 -->|inhibitor| n8
|
| 71 |
+
n6 -->|implicates| n8
|
| 72 |
+
n21 -->|inhibitor| n12
|
| 73 |
+
n6 -->|implicates| n12
|
| 74 |
+
n15 -->|in pathway| n22
|
| 75 |
+
n22 -->|q=0.0064| n0
|
| 76 |
+
n15 -->|in pathway| n23
|
| 77 |
+
n23 -->|q=0.0064| n0
|
| 78 |
+
n8 -->|in pathway| n22
|
| 79 |
+
n22 -->|q=0.0064| n0
|
| 80 |
+
n2 -->|in pathway| n23
|
| 81 |
+
n23 -->|q=0.0064| n0
|
| 82 |
+
classDef drug fill:#ddf4ff,stroke:#0969da,color:#0a3069;
|
| 83 |
+
classDef anchor fill:#eeeeee,stroke:#6e7781,color:#24292f,stroke-dasharray:4 3;
|
| 84 |
+
classDef target fill:#fff8c5,stroke:#9a6700,color:#4d2d00;
|
| 85 |
+
classDef toxin fill:#ffebe9,stroke:#cf222e,color:#5a0f14;
|
| 86 |
+
classDef pathway fill:#dafbe1,stroke:#1a7f37,color:#0a3622;
|
| 87 |
+
classDef disease fill:#fbefff,stroke:#8250df,color:#3b1a5c;
|
| 88 |
+
classDef readout fill:#f6f8fa,stroke:#6e7781,color:#24292f;
|
| 89 |
+
class n1,n10,n13,n14,n16,n17,n18,n19,n20,n21 drug;
|
| 90 |
+
class n7,n9,n11 anchor;
|
| 91 |
+
class n2,n8,n12,n15 target;
|
| 92 |
+
class n3,n4,n5,n6 toxin;
|
| 93 |
+
class n22,n23 pathway;
|
| 94 |
+
class n0 disease;
|
graphs/pd_top10_readouts.mmd
ADDED
|
@@ -0,0 +1,45 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
%% Disease-relevant biomarker readouts (PK excluded)
|
| 2 |
+
flowchart LR
|
| 3 |
+
n0["2. Adalimumab"]
|
| 4 |
+
n1("inflammation")
|
| 5 |
+
n2["1. Etanercept"]
|
| 6 |
+
n3["3. Infliximab"]
|
| 7 |
+
n4("other_biomarker")
|
| 8 |
+
n5["5. Certolizumab"]
|
| 9 |
+
n6["6. Golimumab"]
|
| 10 |
+
n7["10. Bupropion"]
|
| 11 |
+
n8("genomic")
|
| 12 |
+
n9("fluid_molecular")
|
| 13 |
+
n10("imaging")
|
| 14 |
+
n11["9. Phenelzine"]
|
| 15 |
+
n0 -->|87 trials| n1
|
| 16 |
+
n2 -->|64 trials| n1
|
| 17 |
+
n3 -->|43 trials| n1
|
| 18 |
+
n0 -->|20 trials| n4
|
| 19 |
+
n5 -->|18 trials| n1
|
| 20 |
+
n3 -->|15 trials| n4
|
| 21 |
+
n6 -->|14 trials| n1
|
| 22 |
+
n2 -->|10 trials| n4
|
| 23 |
+
n7 -->|5 trials| n1
|
| 24 |
+
n7 -->|5 trials| n4
|
| 25 |
+
n2 -->|5 trials| n8
|
| 26 |
+
n6 -->|4 trials| n4
|
| 27 |
+
n3 -->|3 trials| n8
|
| 28 |
+
n5 -->|2 trials| n4
|
| 29 |
+
n2 -->|2 trials| n9
|
| 30 |
+
n0 -->|2 trials| n8
|
| 31 |
+
n6 -->|1 trials| n9
|
| 32 |
+
n3 -->|1 trials| n9
|
| 33 |
+
n0 -->|1 trials| n10
|
| 34 |
+
n2 -->|1 trials| n10
|
| 35 |
+
n11 -->|1 trials| n8
|
| 36 |
+
n0 -->|1 trials| n9
|
| 37 |
+
classDef drug fill:#ddf4ff,stroke:#0969da,color:#0a3069;
|
| 38 |
+
classDef anchor fill:#eeeeee,stroke:#6e7781,color:#24292f,stroke-dasharray:4 3;
|
| 39 |
+
classDef target fill:#fff8c5,stroke:#9a6700,color:#4d2d00;
|
| 40 |
+
classDef toxin fill:#ffebe9,stroke:#cf222e,color:#5a0f14;
|
| 41 |
+
classDef pathway fill:#dafbe1,stroke:#1a7f37,color:#0a3622;
|
| 42 |
+
classDef disease fill:#fbefff,stroke:#8250df,color:#3b1a5c;
|
| 43 |
+
classDef readout fill:#f6f8fa,stroke:#6e7781,color:#24292f;
|
| 44 |
+
class n0,n2,n3,n5,n6,n7,n11 drug;
|
| 45 |
+
class n1,n4,n8,n9,n10 readout;
|
pd_drug_biomarker_readouts.parquet
ADDED
|
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:91775c706d3a9a4904093ca9bdb350cda81a6a80a49663da5d8180c5fdaac3ee
|
| 3 |
+
size 5623
|
pd_drug_candidates.parquet
ADDED
|
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:e5529a56791aff902518f2bd5cb9a7e6b5c855d367f0ad2090a2aaa34dc7d5bf
|
| 3 |
+
size 13940
|
pd_drug_target_evidence.parquet
ADDED
|
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:a371ea6376d99dc34b6e2ae6ffbf6da5bd93393d20f5ab7b79141cdd71c00118
|
| 3 |
+
size 10137
|
pd_pathway_evidence.parquet
ADDED
|
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:fbaa431f9d6b5021cc60fb3feff73e855e31fc1e44c605d626d4453fa80f46b5
|
| 3 |
+
size 13933
|
pd_ranking_top10.parquet
ADDED
|
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:b4307434816cd7ea5def90a95f6d96097bcd56e9f82ef6e64c282e3496d5c599
|
| 3 |
+
size 8200
|
pd_undrugged_targets.parquet
ADDED
|
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:298cce2bad8eca452f0f879bb2d725c7cf8ac81bd4e0b667ff81ddd03af7d67f
|
| 3 |
+
size 5227
|